[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pacific Biosciences (PACB)

Pacific Biosciences (PACB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 368,063
  • Shares Outstanding, K 310,602
  • Annual Sales, $ 160,010 K
  • Annual Income, $ -546,380 K
  • EBIT $ -130 M
  • EBITDA $ 267 M
  • 60-Month Beta 2.31
  • Price/Sales 2.26
  • Price/Cash Flow 1.48
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 93.78% (-13.99%)
  • Historical Volatility 66.73%
  • IV Percentile 7%
  • IV Rank 11.96%
  • IV High 248.95% on 03/20/26
  • IV Low 72.70% on 07/14/26
  • Expected Move (DTE 10) 0.2295 (19.96%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 781
  • Volume Avg (30-Day) 717
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 70,758
  • Open Int (30-Day) 68,793
  • Expected Range 0.9205 to 1.3795

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 1
  • High Estimate $-0.13
  • Low Estimate $-0.13
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) -8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1200 +2.68%
on 08/10/26
1.5600 -26.28%
on 07/13/26
-0.4100 (-26.28%)
since 07/10/26
3-Month
1.0900 +5.50%
on 05/18/26
1.8350 -37.33%
on 07/02/26
-0.2600 (-18.44%)
since 05/08/26
52-Week
1.0900 +5.50%
on 05/18/26
2.7300 -57.88%
on 01/23/26
-0.2000 (-14.81%)
since 08/08/25

Most Recent Stories

More News
PACB Q2 Deep Dive: Leadership Transition and SPRQ-Nx Rollout Shape Outlook

PACB Q2 Deep Dive: Leadership Transition and SPRQ-Nx Rollout Shape Outlook

PACB : 1.1500 (-2.95%)
PacBio (NASDAQ:PACB) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings

PacBio (NASDAQ:PACB) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings

PACB : 1.1500 (-2.95%)
Pacific Biosciences: Q2 Earnings Snapshot

Pacific Biosciences: Q2 Earnings Snapshot

PACB : 1.1500 (-2.95%)
PacBio Appoints Mark Van Oene as President and Chief Executive Officer

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions, today...

PACB : 1.1500 (-2.95%)
PacBio Announces Second Quarter 2026 Financial Results

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of...

PACB : 1.1500 (-2.95%)
PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the upcoming availability of SPRQ-Nx chemistry...

PACB : 1.1500 (-2.95%)
Can PacBio Finally Show the Market Its Revenue Model Actually Works?

Barchart Research What to Expect from PACB Earnings PACB Generated August 4, 2026 Current Price $1.4400 EPS Estimate $$-0.14 Consensus Rating Moderate Buy Average Move 10.34% Can PacBio Finally Show the...

PACB : 1.1500 (-2.95%)
PacBio (PACB) To Report Earnings Tomorrow: Here Is What To Expect

PacBio (PACB) To Report Earnings Tomorrow: Here Is What To Expect

PACB : 1.1500 (-2.95%)
3 Russell 2000 Stocks That Fall Short

3 Russell 2000 Stocks That Fall Short

EFC : 13.47 (-0.96%)
PACB : 1.1500 (-2.95%)
TTI : 8.65 (+1.65%)
1 Russell 2000 Stock on Our Watchlist and 2 That Underwhelm

1 Russell 2000 Stock on Our Watchlist and 2 That Underwhelm

MGNI : 24.21 (-2.06%)
PACB : 1.1500 (-2.95%)
MAN : 56.52 (-0.14%)

Business Summary

Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA. PacBio's products are based on Single Molecule, Real-Time...

See More

Key Turning Points

3rd Resistance Point 1.2567
2nd Resistance Point 1.2233
1st Resistance Point 1.1867
Last Price 1.1500
1st Support Level 1.1167
2nd Support Level 1.0833
3rd Support Level 1.0467

See More

52-Week High 2.7300
Fibonacci 61.8% 2.1035
Fibonacci 50% 1.9100
Fibonacci 38.2% 1.7165
Last Price 1.1500
52-Week Low 1.0900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.